Cypress Bioscience Inc. (Nasdaq: CYPB) will license BiolineRx's schizophrenia drug for the North American market in a $365 million deal but BiolineRx will retain the rights for the drug outside of North America. The stock price plunged $1.64 to close at $2.70.
Cypress Licenses North American Rights To Schizophrenia Drug
June 21, 2010 at 17:21 PM EDT
